Sponsored by
The GIANT trial has begun enrolling in the United States to test whether neoadjuvant immunotherapy can improve outcomes for people with newly diagnosed glioblastoma (GBM). Led by Dr. Mustafa Khasraw at Duke University, GIANT is a Phase 2 trial evaluating the immune checkpoint inhibitors nivolumab and relatlimab given before surgery, followed by these agents with standard radiotherapy and temozolomide afterward.
Unlike most prior GBM immunotherapy studies, this trial focuses on giving immunotherapy early (before and after initial surgery) based on the idea that an intact, treatment-naive tumor might be more responsive to immune stimulation. Interest in the trial has been heightened by high-profile patient advocates and researchers, including world-renowned melanoma expert Professor Richard Scolyer, who has lived well beyond typical expectations after his own GBM (MGMT unmethylated) diagnosis. More info on the trial can be found HERE.